6 research outputs found
Milk Exosomes Facilitate Oral Delivery of Drugs against Intestinal Bacterial Infections
Biopharmaceutics Classification System (BCS) class II
and IV drugs
exhibit low solubility and suffer a limitation in oral administration.
Exosomes have attracted intensive attention in the efficient delivery
of such compounds. However, low gastrointestinal stability and high
production cost of exosomes hinder their development as drug carriers.
Here, milk exosomes are functionalized with phosphatidylserine and
are capable of improving the solubility of BCS class II and IV drugs,
resulting in facilitating the oral delivery of the drugs. A natural
flavonoid, α-mangostin, is loaded into exosomes (AExo) to enhance
the antibacterial efficiency, demonstrated by clearing 99% of bacteria
in macrophages. Furthermore, AExo exhibits high mucus penetrability
and shows a significant therapeutic efficacy in two animal infection
models. Collectively, this work expands the application of exosomes
from bovine milk with simple operation and low cost, shedding light
on the potential of milk exosomes in improving the solubility of drugs
to enhance the efficacy of oral administration
Electrospun Micropatterned Nanocomposites Incorporated with Cu<sub>2</sub>S Nanoflowers for Skin Tumor Therapy and Wound Healing
Surgical
excision of skin cancers can hardly remove the tumor tissues
completely and simultaneously result in cutaneous defects. To avoid
tumor recurrence and heal the tumor-induced wounds, we designed a
tissue engineering membrane possessing bifunctions of tumor therapy
and skin tissue regeneration. The micropatterned nanocomposite membrane
was successfully fabricated by incorporating Cu<sub>2</sub>S nanoflowers
into biopolymer fibers <i>via</i> a modified electrospinning
method. With uniformly embedded Cu<sub>2</sub>S nanoparticles, the
membranes exhibited excellent and controllable photothermal performance
under near-infrared irradiation, which resulted in high mortality
(>90%) of skin tumor cells and effectively inhibited tumor growth
in mice. Moreover, the membranes supported the adhesion, proliferation,
and migration of skin cells as well as significantly stimulated angiogenesis
and healed full-thickness skin defects <i>in vivo</i>. This
proof-of-concept study offers a facile and reliable strategy for localized
skin tumor therapy and tissue regeneration using bifunctional tissue
engineering biomaterials, showing great promise for tumor-induced
wound healing applications
Copper Silicate Hollow Microspheres-Incorporated Scaffolds for Chemo-Photothermal Therapy of Melanoma and Tissue Healing
The treatment of melanoma requires complete removal of tumor cells
and simultaneous tissue regeneration of tumor-initiated cutaneous
defects. Herein, copper silicate hollow microspheres (CSO HMSs)-incorporated
bioactive scaffolds were designed for chemo-photothermal therapy of
skin cancers and regeneration of skin tissue. CSO HMSs were synthesized
with interior hollow and external nanoneedle microstructure, showing
excellent drug-loading capacity and photothermal effects. With incorporation
of drug-loaded CSO HMSs into the electrospun scaffolds, the composite
scaffolds exhibited excellent photothermal effects and controlled
NIR-triggered drug release, leading to distinctly synergistic chemo-photothermal
therapy of skin cancer both <i>in vitro</i> and <i>in vivo</i>. Furthermore, such CSO HMSs-incorporated scaffolds
could promote proliferation and attachment of normal skin cells and
accelerate skin tissue healing in tumor-bearing and diabetic mice.
Taken together, CSO HMSs-incorporated scaffolds may be used for complete
eradication of the remaining tumor cells after surgery and simultaneous
tissue healing, which offers an effective strategy for therapy and
regeneration of tumor-initiated tissue defects
Clinical characteristics of subjects.
The effects of Covid-19 vaccines on vascular function are still controversial. We evaluated the effects of BNT162b2 vaccine (BioNTech and Pfizer) on endothelial function assessed by flow-mediated vasodilation (FMD) and vascular smooth muscle function assessed by nitroglycerine-induced vasodilation (NID). This study was a prospective observational study. A total of 23 medical staff at Hiroshima University Hospital were enrolled in this study. FMD and NID were measured before vaccination and two weeks and six months after the 2nd dose of vaccination. FMD was significantly smaller two weeks after the 2nd dose of vaccination than before vaccination (6.5±2.4% and 8.2±2.6%, p = 0.03). FMD was significantly larger at six months than at two weeks after the 2nd dose of vaccination (8.2±3.0% and 6.5±2.4%, p = 0.03). There was no significant difference between FMD before vaccination and that at six months after the 2nd dose of vaccination (8.2±2.6% to 8.2±3.0%, p = 0.96). NID values were similar before vaccination and at two weeks, and six months after vaccination (p = 0.89). The BNT162b2 Covid-19 vaccine temporally impaired endothelial function but not vascular smooth muscle function, and the impaired endothelial function returned to the baseline level within six months after vaccination.</div
Fig 1 -
Dot graphs show effects of the BNT162b2 mRNA Covid-19 vaccine on flow-mediated vasodilation (A) and nitroglycerine-induced vasodilation (B) before vaccination and at two weeks and six months after the 2nd dose of vaccination.</p
S1 File -
The effects of Covid-19 vaccines on vascular function are still controversial. We evaluated the effects of BNT162b2 vaccine (BioNTech and Pfizer) on endothelial function assessed by flow-mediated vasodilation (FMD) and vascular smooth muscle function assessed by nitroglycerine-induced vasodilation (NID). This study was a prospective observational study. A total of 23 medical staff at Hiroshima University Hospital were enrolled in this study. FMD and NID were measured before vaccination and two weeks and six months after the 2nd dose of vaccination. FMD was significantly smaller two weeks after the 2nd dose of vaccination than before vaccination (6.5±2.4% and 8.2±2.6%, p = 0.03). FMD was significantly larger at six months than at two weeks after the 2nd dose of vaccination (8.2±3.0% and 6.5±2.4%, p = 0.03). There was no significant difference between FMD before vaccination and that at six months after the 2nd dose of vaccination (8.2±2.6% to 8.2±3.0%, p = 0.96). NID values were similar before vaccination and at two weeks, and six months after vaccination (p = 0.89). The BNT162b2 Covid-19 vaccine temporally impaired endothelial function but not vascular smooth muscle function, and the impaired endothelial function returned to the baseline level within six months after vaccination.</div